We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

94 hedge funds and large institutions have $722M invested in Theravance Biopharma in 2014 Q2 according to their latest regulatory filings, with 94 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

3% less call options, than puts

Call options by funds: $131K | Put options by funds: $135K

Holders
94
Holders Change
+94
Holders Change %
–
% of All Funds
2.7%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
94
Increased
–
Reduced
–
Closed
–
Calls
$131K
Puts
$135K
Net Calls
-$4K
Net Calls Change
-$4K

Top Buyers

Rank Fund Capital Flow
1
BG
Baupost Group
Massachusetts
+$182M
2
Capital World Investors
Capital World Investors
California
+$62.8M
3
IAM
Iridian Asset Management
Connecticut
+$62.3M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$41.3M
5
O
OppenheimerFunds
New York
+$32.7M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
LCM
26
Laurion Capital Management
New York
$3.98M +$3.76M +124,872 New
Bank of New York Mellon
27
Bank of New York Mellon
New York
$3.83M +$3.62M +120,125 New
TCIM
28
TIAA CREF Investment Management
New York
$3.81M +$3.59M +119,378 New
Northern Trust
29
Northern Trust
Illinois
$3.62M +$3.41M +113,378 New
T. Rowe Price Associates
30
T. Rowe Price Associates
Maryland
$3.31M +$3.13M +103,896 New
RA
31
Royce & Associates
New York
$3.23M +$3.05M +101,228 New
State of Wisconsin Investment Board
32
State of Wisconsin Investment Board
Wisconsin
$2.75M +$2.59M +86,200 New
ARC
33
Absolute Return Capital
Massachusetts
$2.62M +$2.47M +82,119 New
GXMC
34
Global X Management Company
New York
$2.61M +$2.47M +81,886 New
SCM
35
Scopia Capital Management
New York
$2.39M +$2.26M +75,000 New
VAM
36
Visium Asset Management
New York
$2.32M +$2.19M +72,743 New
BIM
37
BlackRock Investment Management
Delaware
$2.19M +$2.07M +68,707 New
Charles Schwab
38
Charles Schwab
California
$1.93M +$1.82M +60,385 New
RP
39
Realm Partners
New York
$1.89M +$1.79M +59,419 New
CS
40
Credit Suisse
Switzerland
$1.84M +$1.73M +57,593 New
AllianceBernstein
41
AllianceBernstein
Tennessee
$1.8M +$1.7M +56,634 New
RSCM
42
Rock Springs Capital Management
Maryland
$1.59M +$1.51M +50,000 New
State Board of Administration of Florida Retirement System
43
State Board of Administration of Florida Retirement System
Florida
$1.37M +$1.3M +43,092 New
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$1.37M +$1.29M +42,933 New
RC
45
Roundview Capital
New Jersey
$1.28M +$1.21M +40,111 New
Citadel Advisors
46
Citadel Advisors
Florida
$1.27M +$1.2M +39,699 New
PAM
47
Panagora Asset Management
Massachusetts
$1.19M +$1.12M +37,260 New
PAMU
48
Pictet Asset Management (UK)
United Kingdom
$1.11M +$1.05M +34,970 New
California Public Employees Retirement System
49
California Public Employees Retirement System
California
$1.11M +$1.05M +34,971 New
TA
50
Teachers Advisors
New York
$1.05M +$991K +32,920 New
1
2
3 4

TBPH Hedge Fund Activity: Q2 2014 in Review

94 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2014, worth a combined $722M.

Buyers outnumbered sellers: 94 funds opened new TBPH positions and 0 closed out — a net gain of 94 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Baupost Group, opening a new position worth an estimated $182M.

  • 94 institutional investors held Theravance Biopharma (TBPH) as of Q2 2014, up from 0 in Q1 2014.
  • Funds reported $722M of Theravance Biopharma stock for Q2 2014.
  • 94 funds opened new Theravance Biopharma positions in Q2 2014 and 0 closed out, a net change of +94 holders.
  • The largest Theravance Biopharma buyer in Q2 2014 was Baupost Group, an estimated $182M added.

Based on aggregated 13F filings for Q2 2014.